Emergent Biosolutions was unreliable from the start. There were red flags before they were awarded the hefty contract and continued to live up to their less-than-stellar expectations throughout the manufacturing period.
An assessment written by Carlo de Notaristefani, a manufacturing expert who has overseen production of COVID-19 vaccines for the federal government since last May, was released just days after the contract with Emergent was signed. He highlighted “key risks” and addressed that the company “will have to be monitored closely”.
The $628 million consequence of the federal government’s decision comes from the Trump administrations “Operation Warp Speed” plan which aimed to speed the process of manufacturing vaccines for mass distribution in an impossibly short amount of time.
This past Saturday, the Biden administration put Johnson & Johnson in charge of the manufacturing plant in light of the troublesome events. The site now only manufactures Johnson & Johnson vaccines and has halted AstraZeneca manufacturing altogether.
However, if anything, this only shows the expected consequences of rushing mass vaccination efforts. This is a multi-layered aspect that runs deep through the pandemic. The blood-clotting incidents from the AstraZeneca vaccine and the adverse reactions from Moderna and Pfizer vaccinations (from the hands of less-than-thorough clinical trials), the ill-advised and deceitful manufacturing plants… They all stem from the irrational pressure from the government to instill mass vaccination efforts on its citizens.